160 related articles for article (PubMed ID: 14693409)
21. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes.
Strowig SM; Avilés-Santa ML; Raskin P
Diabetes Care; 2002 Oct; 25(10):1691-8. PubMed ID: 12351463
[TBL] [Abstract][Full Text] [Related]
22. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
23. Effect of troglitazone on body fat distribution in type 2 diabetic patients.
Mori Y; Murakawa Y; Okada K; Horikoshi H; Yokoyama J; Tajima N; Ikeda Y
Diabetes Care; 1999 Jun; 22(6):908-12. PubMed ID: 10372240
[TBL] [Abstract][Full Text] [Related]
24. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes.
Willi SM; Kennedy A; Brant BP; Wallace P; Rogers NL; Garvey WT
Diabetes Res Clin Pract; 2002 Nov; 58(2):87-96. PubMed ID: 12213349
[TBL] [Abstract][Full Text] [Related]
25. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
[TBL] [Abstract][Full Text] [Related]
26. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
[TBL] [Abstract][Full Text] [Related]
27. Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study.
Stakos DA; Schuster DP; Sparks EA; Wooley CF; Osei K; Boudoulas H
J Cardiol; 2003 Apr; 41(4):183-90. PubMed ID: 12728539
[TBL] [Abstract][Full Text] [Related]
28. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.
Imano E; Kanda T; Nakatani Y; Nishida T; Arai K; Motomura M; Kajimoto Y; Yamasaki Y; Hori M
Diabetes Care; 1998 Dec; 21(12):2135-9. PubMed ID: 9839106
[TBL] [Abstract][Full Text] [Related]
29. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
[TBL] [Abstract][Full Text] [Related]
30. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.
Fonseca VA; Valiquett TR; Huang SM; Ghazzi MN; Whitcomb RW
J Clin Endocrinol Metab; 1998 Sep; 83(9):3169-76. PubMed ID: 9745421
[TBL] [Abstract][Full Text] [Related]
31. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
Schwartz S; Raskin P; Fonseca V; Graveline JF
N Engl J Med; 1998 Mar; 338(13):861-6. PubMed ID: 9516220
[TBL] [Abstract][Full Text] [Related]
32. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
Scheen AJ; Lefèbvre PJ
Diabetes Care; 1999 Sep; 22(9):1568-77. PubMed ID: 10480527
[TBL] [Abstract][Full Text] [Related]
33. Metabolic effects of Troglitazone in patients with diet-controlled type 2 diabetes.
Robinson AC; Jeffs JA; Gray RG; Bannister PA; Mather H; Gallagher JJ; Robinson S; Nattrass M; Venkatesan S; Halliday D; Johnston DG
Eur J Clin Invest; 2004 Jan; 34(1):29-36. PubMed ID: 14984435
[TBL] [Abstract][Full Text] [Related]
34. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
Hershon KS; Hershon PM
Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
[TBL] [Abstract][Full Text] [Related]
35. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.
Phillips SA; Ciaraldi TP; Kong AP; Bandukwala R; Aroda V; Carter L; Baxi S; Mudaliar SR; Henry RR
Diabetes; 2003 Mar; 52(3):667-74. PubMed ID: 12606507
[TBL] [Abstract][Full Text] [Related]
36. Effect of vildagliptin on hsCRP and arterial stiffness in patients with type 2 diabetes mellitus.
Zografou I; Sampanis C; Gkaliagkousi E; Iliadis F; Papageorgiou A; Doukelis P; Vogiatzis K; Douma S
Hormones (Athens); 2015; 14(1):118-25. PubMed ID: 25402372
[TBL] [Abstract][Full Text] [Related]
37. Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.
Kato K; Yamada D; Midorikawa S; Sato W; Watanabe T
Metabolism; 2000 May; 49(5):662-5. PubMed ID: 10831180
[TBL] [Abstract][Full Text] [Related]
38. Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group.
Buse JB; Gumbiner B; Mathias NP; Nelson DM; Faja BW; Whitcomb RW
Diabetes Care; 1998 Sep; 21(9):1455-61. PubMed ID: 9727891
[TBL] [Abstract][Full Text] [Related]
39. Anti-inflammatory effects of troglitazone in nondiabetic obese subjects independent of changes in insulin sensitivity.
van Tits LJ; Arioglu-Oral E; Sweep CG; Smits P; Stalenhoef AF; Tack CJ
Neth J Med; 2005; 63(7):250-5. PubMed ID: 16093575
[TBL] [Abstract][Full Text] [Related]
40. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial.
Caballero AE; Saouaf R; Lim SC; Hamdy O; Abou-Elenin K; O'Connor C; Logerfo FW; Horton ES; Veves A
Metabolism; 2003 Feb; 52(2):173-80. PubMed ID: 12601628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
